Full text is available at the source.
Abstract
Migraine intensity scores decreased significantly in both the probiotic and placebo groups (P<0.001).
- The Migraine Disability Assessment Scale (MIDAS) scores improved for all participants.
- The Headache Disability Inventory (HDI) score decreased significantly in the probiotic group (P=0.032) and showed a borderline decrease in the placebo group (P=0.053).
- Probiotic group patients reported a median of 6 migraine days in the first month, compared to 5 days in the placebo group, with no significant difference across the months.
- A reduction of 2 or more migraine days was observed in 12 out of 31 patients in the probiotic group compared to 7 out of 29 in the placebo group, which was not statistically significant.
- Probiotic treatment did not significantly alter medication use, intestinal permeability, or inflammation when compared to the placebo.
Simplified